A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma

Abstract

We report a case of ocular drug toxicity consistent with bilateral Vogt-Koyanagi-Harada (VKH) like disease in a patient with cutaneous melanoma treated with Dabrafenib/Trametinib therapy. A 53-year-old man with a history of metastatic cutaneous melanoma, treated with Dabrafenib/Trametinib, developed a severe acute panuveitis with granulomatous anterior uveitis and multiple serous retinal detachments. The ocular inflammatory reaction was classified as a bilateral Vogt-Koyanagi-Harada disease. Intraocular inflammation resolved after discontinuation of chemotherapeutic agents and aggressive topical and systemic corticosteroid therapy. The present case outlines the importance of recognizing VKH-like syndrome as a possible consequence of therapy with dabrafenib and trametinib.

Keywords

Immunology choroidal/retinal inflammation UVEA panuveitis UVEITIS systemic drug retinal toxicity RETINA pharmacology

Get full access to this article

View all access options for this article.

References

Chapman

Hauschild

Robert

, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507–2516.

Diamantopoulos

Stoungioti

Anastasopoulou

, et al. Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. Melanoma Res 2018; 28: 648–651.

Cicinelli

Giuffré

Marchese

, et al. The bacillary detachment in posterior segment ocular diseases. Ophthalmol Retin 2019; 4(4): 454–456.

Lim

Lomax

McNeil

, et al. Uveitis and papillitis in the setting of dabrafenib and trametinib therapy for metastatic melanoma: a case report. Ocul Immunol Inflamm 2018; 26(4): 628–631.

Méndez-Martínez

Calvo

Ruiz-Moreno

, et al. Ocular adverse events associated with mek inhibitors. Retina 2019; 39(8): 1435–1450.

Francis

Habib

Abramson

, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 2017; 124(12): 1788–1798.

Choe

McArthur

Caro

, et al. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 2014; 158(4): 831–837.e2.

Sober

Haynes

HA.

Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma. Arch Dermatol 1978; 114(3): 439–441.

Stein

ZL.

Malignant melanoma and Vogt–Koyanagi–Harada syndrome. Am J Hosp Pharm 1980; 37: 1306.

10.

Aisenbrey

Lüke

Ayertey

, et al. Vogt–Koyanagi–Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up. Graefes Arch Clin Exp Ophthalmol 2003; 241(12): 996–999.